Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
126 studies found for:    "Expanded Access" [STUDY-TYPES] | Open Studies
Show Display Options
Rank Status Study
1 Available An Extended Access Program for Perampanel
Condition: Partial Onset Seizures
Intervention: Drug: Perampanel
2 Available Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
Condition: Chronic Myeloid Leukemia
Intervention: Drug: bosutinib
3 Available Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
Condition: Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4 DAP
4 Available Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver Disease
Conditions: Cholestasis;   Short Bowel Syndrome
Intervention: Drug: Omegaven
5 Available 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
Conditions: Lambert-Eaton Myasthenic Syndrome (LEMS);   Congenital Myasthenia (CM)
Intervention: Drug: 3,4-diaminopyridine
6 Available Prevention of Transmission of Sexually Transmitted Diseases in the Youth Through Effective Intervention,
Condition: HIV
Intervention: Behavioral: Lifestyle Counseling
7 Available Expanded Access Study of Amifampridine Phosphate in LEMS, Congenital Myasthenic Syndrome, or Downbeat Nystagmus Patients
Conditions: Lambert-Eaton Myasthenic Syndrome;   Congenital Myasthenic Syndrome;   Downbeat Nystagmus
Intervention: Drug: Amifampridine Phosphate
8 Available TX2® Low Profile TAA Endovascular Graft
Conditions: Aortic Aneurysm;   Penetrating Ulcer;   Vascular Disease
Intervention: Device: Zenith® TX2® Low Profile TAA Endovascular Graft (Thoracic Aortic Aneurysm)
9 Unknown  Weight-bearing Measuring Device to Determine Normative Percentage Body-Weight/Weight-Bearing Values and Weight-bearing Gait Characteristics
Conditions: Percentage Body-Weight;   Weight-Bearing Values;   Weight-bearing Gait Characteristics
Intervention: Device: SmartStep insole
10 Available Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG)
11 Available 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
Conditions: Carcinoid Tumors;   Islet Cell (Pancreatic NET);   Other Neuroendocrine Tumors
Intervention: Drug: 68Ga-DOTA TATE
12 Unknown  HIV-discordant Couple Intrauterine Insemination
Conditions: Infertility;   HIV Infections
Interventions: Other: Sperm washing and testing for HIV contamination;   Procedure: Intrauterine Insemination
13 Unknown  Using Hypnotherapy For Dementia & Alzheimer's
Condition: Alzheimer Disease
Intervention: Other: Hypnotherapy
14 Available Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
Condition: Unresected Stage IIIb to IVM1c Melanoma
Intervention: Drug: Talimogene Laherparepvec
15 Available Treatment Use of Domperidone for Gastroparesis
Conditions: Gastroesophageal Reflux Disease;   GERD;   Gastroparesis
Intervention: Drug: Domperidone
16 Available Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
Condition: Patient 0001-000412 Under Study P05538
Intervention: Drug: ficlatuzumab
17 Available 131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Pheochromocytoma
Conditions: Neuroblastoma;   Childhood Metastatic Pheochromocytoma
Interventions: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG);   Drug: 131 I-MIBG
18 Available Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Panobinostat
19 Available International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer
Conditions: Metastatic Gastric Cancer;   Metastatic Adenocarcinoma of the Gastroesophageal Junction
Intervention: Biological: Ramucirumab
20 Available Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis;   Cytopenias;   White Blood Cell Abnormalities;   Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years